AngeLab Awarded
Receives European Innovation Award

AngeLab Prenatal Disease Testing Project receives European Innovation Award

The project seeks to minimize current invasive techniques by developing diagnostic devices that are safer, more accessible and cheaper than current techniques for detecting genetic diseases before birth.The initiative has been acknowledged with the Innovation Award as the best European H2020/FP7 project at the European Nanoelectronics Forum

  • The project began in 2012 with the objective to develop faster, cheaper and less invasive prenatal analysis systems than current ones.
  • The project gathered companies and public institutions in the world of prenatal diagnosis, research experts in Lab-on-a-Chip system integration and Molecular Biology, plus manufacturers with a budget of 11 million euros.
  • This system first separates and then analyzes the foetal DNA from maternal blood detecting the most common prenatal genetic conditions such as Down syndrome or fetal RHD.
  • Currently, the technical verification phase of the developments is taking place in the hospitals that collaborate with the initiative.

Rome, November 23, 2016. The AngeLab project has been acknowledged by the European Commission as one of the most innovative Horizon2020/FP7 projects in the area of “Micro/Nano Electronics”, “Smart System Integration”, or “Thin Organic Large Area Electronics”. It received an Innovation Awards today in Rome in the framework European Nanoelectronics Forum.

The award, which distinguishes the most outstanding project among those that have received funding from the European Union through the Horizon 2020 and Framework Programme 7 (FP7) research & innovation support programmes, has been received by the coordinator of AngeLab, Dr. Jesús M. Ruano López, from the technology centre IK4-Ikerlan, in the ceremony held this afternoon.

AngeLab (A New GEnetic LABoratory for non-invasive prenatal diagnosis) was established in 2012, with a budget of 11 million euro, focussing on the development of a line of systems based on lab-on-a-chip technology, capable of detecting foetus genetic conditions by analysing the mother’s blood.

The development of the devices in the context of Angelab project constitutes the starting point for other pioneering systems that are not covered by any international or other research projects currently underway (recessive conditions or even dominant ones).

After the pilot production of the new devices, the systems are being technically validated with patients through more than 400 diagnostic tests carried out in centres of the Basque Health Service (Osakidetza).

IK4-IKERLAN coordinates a broad consortium of research centers, universities, and companies across Europe. In addition to Osakidetza (Basque Health Service): Hospital Universitario Basurto, Hospital Universitario Donostia and Biodonostia, DNA Data from Spain, CAN (Germany), NIPD Genetics and the Cyprus Institute of Neurology and Genetics from Cyprus, EVGroup (Austria), Ademtech (France) and Biopharma (UK) take part as the business part of the consortium. The consortium is completed by GAIKER- IK4 and Fundacion Rioja Salud from Spain, Hahn-Schickard from Germany, and WUT from Poland.

The project is scheduled to end next year.